Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROXI-CAT-II
NCT07493304Phase 3Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Aug 2026
- Primary completion
- Jul 2031
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of REGN7508 in venous thromboembolism (VTE) (2 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Occurrence of Treatment-Emergent Adverse Events at 6 months, Severity of Treatment-Emergent Adverse Events at 6 months and 2 more. Started Aug 2026; status: recruiting.
02
Drugs
REGN7508
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT07493304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07493304.